Skip to Content

Investors are betting big on ­Regeneron: Its market value has jumped by more than a fifth in 2017. Why? Sales of eye-­disease treatment Eylea are strong. The company’s expansive pipeline could continue to fuel steady growth. Regeneron has 11 experimental treatments in Phase II or Phase III clinical trials. One that could prove critical is REGN2810, a type of next-generation medicine currently in late-stage studies that harnesses the body’s immune system to fight cancer.

Company Information

Overall Score2.5
Sector
Health Care
Industry
Pharmaceuticals
CEO
Leonard S. Schleifer
Websitehttp://www.regeneron.com
Employees5,400
HQ Location
Tarrytown, N.Y.
Revenues ($M) (Past 12 Months)$5,236
Profits ($M) (Past 12 Months)$1,155
Market Value as of Oct. 9, 2017 ($M)$50,054